COX-2 Mediates Immune Evasion and Decreases Chemosensitivity in Breast Cancer Through Activation of the JAK2/STAT3 Signalling Pathway.

Experimental findings show COX-2 activation decreases chemosensitivity and promotes immune evasion, suggesting critical therapy targets.